<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168984</url>
  </required_header>
  <id_info>
    <org_study_id>UP0039</org_study_id>
    <secondary_id>2017-000385-30</secondary_id>
    <nct_id>NCT03168984</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects</brief_title>
  <official_title>A Single-Centre, Investigator/Subject Blind, Placebo-Controlled, Single and Multiple Oral Dose Investigation of Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of
      UCB0942 in Japanese and Caucasian subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Actual">August 14, 2017</completion_date>
  <primary_completion_date type="Actual">August 14, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax: maximum observed plasma concentration of UCB0942 and metabolites</measure>
    <time_frame>Plasma will be collected predose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t): area under the plasma concentration-time curve from time zero to the time of last detectable concentration for UCB0942 and metabolites</measure>
    <time_frame>Plasma will be collected predose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours postdose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax: time of maximum concentration of UCB0942 and metabolites during the Single-dose period</measure>
    <time_frame>Plasma will be collected predose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax: time of maximum concentration of UCB0942 and metabolites during the Multiple-dose period</measure>
    <time_frame>Plasma will be collected predose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC: area under the plasma concentration-time curve from time zero to infinity for UCB0942 and metabolites during the Single-dose period</measure>
    <time_frame>Plasma will be collected predose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours postdose.</time_frame>
    <description>AUC is calculated as AUC(0-t)+Clast/kel, where Clast is the last observed quantifiable plasma concentration and kel is the apparent terminal elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2: apparent terminal elimination half-life of UCB0942 and metabolites during the Single-dose period</measure>
    <time_frame>Plasma will be collected predose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2: apparent terminal elimination half-life of UCB0942 and metabolites during the Multiple-dose period</measure>
    <time_frame>Plasma will be collected predose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RCmax: Accumulation ratio of Cmax for UCB0942 and metabolites during the Multiple-dose period</measure>
    <time_frame>Plasma will be collected predose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau: area under the curve over a dosing interval (12hrs) for UCB0942 and metabolites during the Single-dose period</measure>
    <time_frame>Plasma will be collected predose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau: area under the curve over a dosing interval (12hrs) for UCB0942 and metabolites during the Multiple-dose period</measure>
    <time_frame>Plasma will be collected predose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAUC: Accumulation ratio of AUCtau for UCB0942 and metabolites during the Multiple-dose period</measure>
    <time_frame>Plasma will be collected predose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) reported spontaneously by the subject or observed by the investigator</measure>
    <time_frame>From Screening until safety follow up visit (up to Week 18)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory variables, vital sign variables, 12-lead ECG variables and physical examination</measure>
    <time_frame>From Baseline until safety follow up visit (up to Week 18)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Japanese and Caucasian Subjects</condition>
  <arm_group>
    <arm_group_label>UCB0942</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 (Japanese subjects): Single dose of UCB0942 (dosage regimen 1) Cohort 2 (Japanese subjects): Single dose of UCB0942 (dosage regimen 2) Cohort 3 (Japanese subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2) Cohort 4 (Caucasian subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 1 and Cohort 2: Single dose of Placebo Cohort 3 and Cohort 4: Single dose of Placebo followed, after maximum 21 days, by multiple doses of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCB0942</intervention_name>
    <description>Pharmaceutical form: Film-coated tablet
Route of administration: Oral use</description>
    <arm_group_label>UCB0942</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: Film-coated tablet
Route of administration: Oral use</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female and between 20 and 55 years of age (inclusive)

          -  Subject is in good physical and mental health

          -  Female subjects will use an efficient form of contraception for the duration of the
             study (unless menopausal)

          -  Male subject agrees that, during the study period, when having sexual intercourse with
             a woman of childbearing potential, he will use an efficient barrier contraceptive AND
             that the respective partner will use an additional efficient contraceptive method

          -  For Japanese subjects: Subject is of Japanese descent as evidenced by appearance and
             verbal confirmation of familial heritage (a subject has all 4 Japanese grandparents
             born in Japan)

          -  For Caucasians: Subject is of Caucasian descent as evidenced by appearance and verbal
             confirmation of familial heritage (a subject has 4 Caucasian grandparents).

        Exclusion Criteria:

        At screening:

          -  Previous study participation with another investigational medicinal product (IMP)
             within 3 months

          -  History of alcohol/drug abuse

          -  History of psychiatric condition and suicide attempt

          -  Any medical condition unfit for study (including history of cancer)

          -  History of hypersensitivity for IMP components

          -  Taking concomitant medications

          -  Positive for human immunodeficiency virus (HIV)/ hepatitis B virus (HBV)/ hepatitis C
             virus (HCV)

          -  Abnormal liver function tests (LFTs), abnormal safety bloods/ vitals/ physical
             examination and electrocardiogram (ECG) findings

          -  Positive for pregnancy test

          -  Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>+1 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Up0039 001</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Japanese subjects</keyword>
  <keyword>Healthy Caucasian subjects</keyword>
  <keyword>UCB0942</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

